Mod­er­na cuts back on man­u­fac­tur­ing; Lil­ly eyes Moun­jaro sup­ply boost; GSK’s shin­gles vac­cine ‘un­con­strained’

End­points News dug in­to this week’s earn­ings calls to gath­er bio­phar­ma man­u­fac­tur­ing up­dates. We found that Mod­er­na is cut­ting its man­u­fac­tur­ing ac­tiv­i­ties, while Am­gen pro­vid­ed up­dates on two fa­cil­i­ty builds.

Mod­er­na has start­ed down­siz­ing its man­u­fac­tur­ing in the third quar­ter as the Covid-19 pan­dem­ic shifts to an epi­dem­ic. The com­pa­ny’s man­u­fac­tur­ing foot­print was “built for a pan­dem­ic,” chief fi­nan­cial of­fi­cer James Mock said on an earn­ings call Thurs­day. Mod­er­na is un­der­go­ing “con­tin­u­ous im­prove­ment projects to dri­ve a re­duc­tion in cost of man­u­fac­tur­ing,” CEO Stéphane Ban­cel added, ac­cord­ing to an Al­phaSense tran­script.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER